NR1I2 and breast cancer: Based on the possibility that PRMT1 may be an important co-activator of PXR and PXR serves as a pivotal activator of P-gp, we supposed that PRMT1 inhibitor may decrease the expression of P-gp in resistant breast cancer cells.